Eleven Biotherapeutics Company Profile (NASDAQ:EBIO)

About Eleven Biotherapeutics (NASDAQ:EBIO)

Eleven Biotherapeutics logoEleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company's product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company's therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EBIO
  • CUSIP: N/A
  • Web: www.elevenbio.com
Capitalization:
  • Market Cap: $20.32 million
  • Outstanding Shares: 24,707,000
Average Prices:
  • 50 Day Moving Avg: $1.41
  • 200 Day Moving Avg: $1.54
  • 52 Week Range: $0.90 - $3.23
P/E:
  • Trailing P/E Ratio: 12.11
  • Foreward P/E Ratio: -0.71
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $29.9 million
  • Price / Sales: 1.09
  • Book Value: $1.05 per share
  • Price / Book: 1.26
Profitability:
  • EBITDA: $9.65 million
  • Net Margins: 11.28%
  • Return on Equity: 4.26%
  • Return on Assets: 1.57%
Debt:
  • Current Ratio: 4.27%
  • Quick Ratio: 4.27%
Misc:
  • Average Volume: 296,592 shs.
  • Beta: 3.49
  • Short Ratio: 14.3
 

Frequently Asked Questions for Eleven Biotherapeutics (NASDAQ:EBIO)

What is Eleven Biotherapeutics' stock symbol?

Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."

How were Eleven Biotherapeutics' earnings last quarter?

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) announced its earnings results on Monday, August, 14th. The company reported ($0.30) earnings per share for the quarter. Eleven Biotherapeutics had a net margin of 11.28% and a return on equity of 4.26%. View Eleven Biotherapeutics' Earnings History.

Who are some of Eleven Biotherapeutics' key competitors?

Who are Eleven Biotherapeutics' key executives?

Eleven Biotherapeutics' management team includes the folowing people:

  • Daniel S. Lynch, Chairman of the Board
  • Stephen A. Hurly, President, Chief Executive Officer, Director
  • John J McCabe, Principal Financial Officer, Principal Accounting Officer
  • Glen C. MacDonald Ph.D., Chief Scientific Officer
  • Gregory P. Adams Ph.D., Chief Development Officer
  • Arthur P. DeCillis M.D., Chief Medical Officer
  • Abbie C. Celniker Ph.D., Director
  • Paul G. Chaney, Director
  • Wendy L. Dixon Ph.D., Director
  • Jay S. Duker MD., Director

How do I buy Eleven Biotherapeutics stock?

Shares of Eleven Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eleven Biotherapeutics' stock price today?

One share of Eleven Biotherapeutics stock can currently be purchased for approximately $1.32.


MarketBeat Community Rating for Eleven Biotherapeutics (NASDAQ EBIO)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  46 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  103
MarketBeat's community ratings are surveys of what our community members think about Eleven Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Eleven Biotherapeutics (NASDAQ:EBIO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Eleven Biotherapeutics (NASDAQ:EBIO)
Price Target History for Eleven Biotherapeutics (NASDAQ:EBIO)
Analysts' Ratings History for Eleven Biotherapeutics (NASDAQ:EBIO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/19/2016Citigroup Inc.DowngradeBuy -> NeutralN/AView Rating Details
1/18/2016Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Eleven Biotherapeutics (NASDAQ:EBIO)
Earnings by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)
Earnings History by Quarter for Eleven Biotherapeutics (NASDAQ EBIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.30)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.25)$0.43 millionViewListenView Earnings Details
3/24/2017Q4 2016($0.12)($0.20)$0.83 millionViewN/AView Earnings Details
11/14/2016Q3($0.17)$0.91$28.70 millionViewListenView Earnings Details
8/12/2016Q2($0.33)$0.28 millionViewN/AView Earnings Details
3/24/2016Q4($0.32)($0.53)$0.57 millionViewN/AView Earnings Details
11/4/2015Q315($0.44)($0.50)$0.10 million$0.07 millionViewListenView Earnings Details
8/13/2015Q215($0.43)($0.36)$0.20 million$0.11 millionViewListenView Earnings Details
4/30/2015Q115($0.57)($0.36)$0.20 million$0.24 millionViewListenView Earnings Details
3/4/2015Q414($0.33)($0.49)$0.80 million$0.38 millionViewListenView Earnings Details
11/13/2014Q314($0.45)($0.66)$0.70 million$0.54 millionViewN/AView Earnings Details
8/13/2014Q2 2014($0.47)($0.51)$0.10 million$0.76 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eleven Biotherapeutics (NASDAQ:EBIO)
Current Year EPS Consensus Estimate: $-1.75 EPS
Next Year EPS Consensus Estimate: $-1.85 EPS

Dividends

Dividend History for Eleven Biotherapeutics (NASDAQ:EBIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Eleven Biotherapeutics (NASDAQ:EBIO)
Insider Ownership Percentage: 21.00%
Institutional Ownership Percentage: 5.05%
Insider Trades by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)
Institutional Ownership by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)
Insider Trades by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2016Abbie CelnikerDirectorSell10,031$3.00$30,093.00View SEC Filing  
9/23/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell443,422$3.16$1,401,213.52View SEC Filing  
9/21/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell322,723$3.75$1,210,211.25View SEC Filing  
9/20/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell53,917$3.39$182,778.63View SEC Filing  
9/19/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell9,700$3.31$32,107.00View SEC Filing  
9/15/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell46,692$4.18$195,172.56View SEC Filing  
9/7/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell129,497$4.54$587,916.38View SEC Filing  
8/15/2016John J MccabeCFOSell1,170$4.80$5,616.00View SEC Filing  
6/27/2016Abbie CelnikerCEOSell10,029$2.08$20,860.32View SEC Filing  
6/27/2016Karen L TubridyInsiderSell4,372$2.08$9,093.76View SEC Filing  
6/13/2016Boxer Capital, LlcMajor ShareholderSell1,042,000$2.74$2,855,080.00View SEC Filing  
2/16/2016John J MccabeSVPSell1,501$0.27$405.27View SEC Filing  
12/28/2015Abbie CelnikerCEOSell10,155$2.85$28,941.75View SEC Filing  
12/28/2015Eric Steven FurfineInsiderSell4,652$2.85$13,258.20View SEC Filing  
5/8/2015Jafco Super V3 Investment LimiMajor ShareholderSell33,400$13.23$441,882.00View SEC Filing  
2/2/2015Jafco Super V3 Investment LimiMajor ShareholderSell17,900$11.62$207,998.00View SEC Filing  
1/30/2015Jafco Super V3 Investment LimiMajor ShareholderSell120,000$11.62$1,394,400.00View SEC Filing  
1/26/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.85$74,655.00View SEC Filing  
1/22/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.82$74,466.00View SEC Filing  
1/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,100$12.07$73,627.00View SEC Filing  
8/26/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.54$23,080.00View SEC Filing  
8/20/2014Jafco Super V3 Investment LimiMajor ShareholderSell1,165$11.54$13,444.10View SEC Filing  
8/18/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,600$11.81$30,706.00View SEC Filing  
8/14/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.75$23,500.00View SEC Filing  
2/11/2014Jafco Super V3 Investment LimiMajor ShareholderBuy219,790$10.00$2,197,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Eleven Biotherapeutics (NASDAQ:EBIO)
Latest Headlines for Eleven Biotherapeutics (NASDAQ:EBIO)
Source:
DateHeadline
streetinsider.com logoEleven Biotherapeutics (EBIO) Names Richard Fitzgerald as Interim CFO - StreetInsider.com
www.streetinsider.com - October 14 at 10:54 PM
streetinsider.com logoEleven Biotherapeutics (EBIO) Names Richard Fitzgerald as Interim CFO
www.streetinsider.com - October 13 at 11:39 PM
finance.yahoo.com logoEleven Biotherapeutics Appoints Richard Fitzgerald as Interim Chief Financial Officer
finance.yahoo.com - October 13 at 6:38 PM
americanbankingnews.com logoFinancial Analysis: Eleven Biotherapeutics (EBIO) vs. Clovis Oncology (CLVS)
www.americanbankingnews.com - October 12 at 8:12 AM
americanbankingnews.com logoEleven Biotherapeutics (EBIO) versus Its Rivals Head-To-Head Contrast
www.americanbankingnews.com - September 30 at 12:30 AM
streetinsider.com logoEleven Biotherapeutics (EBIO) Completes Vicinium Manufacturing for Ongoing Clinical Trials in NMIBC - StreetInsider.com
www.streetinsider.com - September 22 at 8:46 AM
finance.yahoo.com logoEleven Biotherapeutics Announces Completion of Vicinium Manufacturing for Ongoing Clinical Trials in Non-Muscle Invasive Bladder Cancer
finance.yahoo.com - September 22 at 8:46 AM
seekingalpha.com logoEleven Bio breaks out, shares ahead 38% - Seeking Alpha
seekingalpha.com - September 9 at 5:02 AM
finance.yahoo.com logoEleven Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 5 at 7:44 PM
americanbankingnews.com logoEleven Biotherapeutics, Inc. (EBIO) Posts Earnings Results
www.americanbankingnews.com - August 15 at 1:10 PM
finance.yahoo.com logoEdited Transcript of EBIO earnings conference call or presentation 14-Aug-17 12:00pm GMT
finance.yahoo.com - August 14 at 11:29 PM
businesswire.com logoEleven Biotherapeutics Reports Second Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - August 14 at 6:27 PM
finance.yahoo.com logoEleven Biotherapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 6:27 PM
finance.yahoo.com logoEleven Biotherapeutics to Report Second Quarter 2017 Financial Results on Monday, August 14, 2017
finance.yahoo.com - August 7 at 6:25 PM
businesswire.com logoEleven Biotherapeutics to Present at Canaccord Genuity 37 - Business Wire (press release)
www.businesswire.com - August 3 at 5:07 PM
finance.yahoo.com logoEleven Biotherapeutics to Present at Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 5:07 PM
prnewswire.com logoToday's Research Report Coverage on Biotech Stocks -- Eleven Biotherapeutics, Egalet, Aevi Genomic Medicine, and ... - PR Newswire (press release)
www.prnewswire.com - July 18 at 7:38 PM
finance.yahoo.com logoETFs with exposure to Eleven Biotherapeutics, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 7:26 PM
seekingalpha.com logoEleven Biotherapeutics (EBIO) Presents At 2017 Marcum Microcap Conference - Slideshow
seekingalpha.com - June 20 at 12:38 AM
streetinsider.com logoEleven Biotherapeutics (EBIO) to Partner with AstraZeneca (AZN) & National Cancer Institute on Development of ... - StreetInsider.com
www.streetinsider.com - June 6 at 10:16 PM
businesswire.com logoEleven Biotherapeutics Announces Data and Safety Monitoring Board (DSMB) Recommendation to Continue Phase 3 Registration Trial with Vicinium™ in Non-Muscle Invasive Bladder ...
www.businesswire.com - June 2 at 4:19 PM
streetinsider.com logoEleven Biotherapeutics (EBIO) Report Data & Safety Monitoring Board Recommendation to Continue Phase 3 ... - StreetInsider.com
www.streetinsider.com - June 1 at 5:36 PM
streetinsider.com logoEleven Biotherapeutics (EBIO) Report Data & Safety Monitoring Board Recommendation to Continue Phase 3 ... - StreetInsider.com
www.streetinsider.com - June 1 at 5:36 PM
businesswire.com logoEleven Biotherapeutics Continues Expansion of Clinical ... - Business Wire (press release)
www.businesswire.com - May 17 at 4:54 PM
streetinsider.com logoEleven Biotherapeutics (EBIO) Presents New Preclinical Data With ... - StreetInsider.com
www.streetinsider.com - April 4 at 7:07 AM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - April 4 at 7:07 AM
streetinsider.com logoEleven Biotherapeutics (EBIO) to Present New Preclinical Data at AACR
www.streetinsider.com - March 28 at 12:04 PM
baystreet.ca logoEleven Biotherapeutics (EBIO) Gains Ahead of Q4 Earnings
www.baystreet.ca - March 26 at 4:36 PM
biz.yahoo.com logoQ4 2016 Eleven Biotherapeutics Inc Earnings Release - Time Not Supplied
biz.yahoo.com - March 24 at 9:40 AM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 24 at 9:40 AM
seekingalpha.com logoEleven Biotherapeutics (EBIO) Presents At Oppenheimer 27th Annual Healthcare Conference
seekingalpha.com - March 22 at 4:59 PM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 7 at 11:55 AM
seekingalpha.com logoEleven Biotherapeutics (EBIO) Presents At 19th Annual BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 16 at 8:41 PM
seekingalpha.com logoEleven Biotherapeutics (EBIO) Presents At 19th Annual BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 16 at 8:41 PM
prnewswire.com logoHow These Biotech Stocks are Faring? -- Agenus, Tokai Pharma, Eleven Biotherapeutics, and Rexahn Pharma - PR Newswire (press release)
www.prnewswire.com - February 14 at 5:46 PM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - January 6 at 5:23 PM

Social

Chart

Eleven Biotherapeutics (EBIO) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.